1% versus 1.3%) [163]. Post hoc analyses of previous main trials on alendronate, risedronate and ibandronate having involved about 30,000 patients did not show any clear-cut association with atrial fibrillation [164–166]. It is possible that a lot of BP-treated patients have increased risks of cardiovascular events already before Acadesine mouse the start of therapy [167, 168]. Also, any potential

cardiovascular risk should be weighted against the benefits of BP therapy. These include the well-documented antifracture efficacy, of course, but may also include additional benefits like the mortality benefit after hip fracture with zoledronic acid therapy, a 30% mortality reduction not simply attributable to anti-fracture efficacy [163, 169]. Bisphosphonate and hypocalcaemia BPs and in particular n-BPs are potent inhibitors

of osteoclastic bone resorption. They can therefore provoke hypocalcaemia, hypocalciuria and PTH reaction in some cases. Etidronate, however, did not induce any fall in serum Caspase Inhibitor VI in vitro and urine calcium because it acutely impaired the accretion of calcium into bone, offsetting a hypocalcaemic response [170]. Even with intravenous potent n-BPs, symptomatic hypocalcaemia rarely occurs in the treatment of osteoporosis under usual conditions, i.e. with supplemental calcium and vitamin D, lack of pre-existing hypoparathyroidism and/or renal failure. Miscellaneous Skin reactions like rash, pruritus and urticaria have been rarely reported with BP use. Re-challenge was positive in some cases [171]. Change of BP was not always accompanied by resurgence of symptoms, suggesting that BP-induced cutaneous reactions ADP ribosylation factor are probably not attributable to a class effect [171]. Extremely rare case reports of damage

to the oral mucosa, apparently not related to osteonecrosis of the jaw, have been reported with the incorrect administration of n-BPs. Discontinuation of the inappropriate use allowed healing of the mucosa ulcers, even with maintained oral intake, but taken according to the prescription instructions [172]. A few reports of transient hepatitis after months to years of alendronate and/or risedronate, with liver biopsies compatible with a drug-induced toxicity, have been described [173, 174]. Healing occurred soon or later after stopping the drug. Bisphosphonates and cancer BPs constitute an ACP-196 datasheet efficacious therapy in order to prevent skeletal complications in patients with bone metastases. They might help to maintain functional independence and quality of life [175]. Several BPs have shown some efficacy in this regard, but owing to its easy mode of administration and its potency, zoledronic acid became the most used drug. Improved quality of life and prolonged disease-free survival have been observed with adjuvant therapy with zoledronic acid.